IRIS
AMATA, EMANUELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.439
EU - Europa 2.616
AS - Asia 1.591
AF - Africa 404
SA - Sud America 308
OC - Oceania 10
Totale 8.368
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.336
IT - Italia 1.248
SG - Singapore 737
CN - Cina 452
DE - Germania 390
IE - Irlanda 352
CI - Costa d'Avorio 292
BR - Brasile 287
HK - Hong Kong 214
FI - Finlandia 163
RU - Federazione Russa 105
UA - Ucraina 98
CA - Canada 87
SN - Senegal 83
FR - Francia 47
GB - Regno Unito 39
ES - Italia 36
KR - Corea 36
VN - Vietnam 32
NL - Olanda 28
JP - Giappone 26
CZ - Repubblica Ceca 25
IN - India 24
BD - Bangladesh 17
PL - Polonia 15
AT - Austria 14
SE - Svezia 14
BE - Belgio 12
UZ - Uzbekistan 12
CH - Svizzera 9
MX - Messico 9
GR - Grecia 8
TR - Turchia 8
AR - Argentina 7
AU - Australia 7
EC - Ecuador 6
ZA - Sudafrica 6
AE - Emirati Arabi Uniti 5
IQ - Iraq 5
IL - Israele 4
KE - Kenya 4
NG - Nigeria 4
CL - Cile 3
CO - Colombia 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
HU - Ungheria 3
KZ - Kazakistan 3
MA - Marocco 3
PK - Pakistan 3
TN - Tunisia 3
BG - Bulgaria 2
CM - Camerun 2
EG - Egitto 2
ET - Etiopia 2
IR - Iran 2
JO - Giordania 2
LB - Libano 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PE - Perù 2
TH - Thailandia 2
AL - Albania 1
AZ - Azerbaigian 1
BB - Barbados 1
CR - Costa Rica 1
JM - Giamaica 1
LT - Lituania 1
LU - Lussemburgo 1
ME - Montenegro 1
MK - Macedonia 1
NC - Nuova Caledonia 1
NP - Nepal 1
OM - Oman 1
PS - Palestinian Territory 1
RO - Romania 1
SA - Arabia Saudita 1
TT - Trinidad e Tobago 1
Totale 8.368
Salva come PNG Salva come JPEG
Città #
Santa Clara 642
Chandler 617
Singapore 427
Dublin 350
Catania 345
Chicago 320
Munich 299
Abidjan 292
Ashburn 194
Boardman 144
Civitanova Marche 130
Helsinki 120
Jacksonville 104
Nanjing 96
Andover 89
Cambridge 88
Lawrence 88
Dakar 83
Hefei 68
Houston 63
Toronto 59
Naples 51
Bremen 48
Des Moines 47
Rome 44
Columbus 36
Seoul 35
The Dalles 35
Beijing 28
Saint Petersburg 27
Wilmington 27
Council Bluffs 26
Tokyo 25
Milan 24
Nanchang 24
Hebei 22
Los Angeles 21
São Paulo 21
Messina 19
Dong Ket 18
Jiaxing 18
Palermo 18
Sala Baganza 18
Brno 17
Jyväskylä 17
Rio de Janeiro 17
Shenyang 17
Ottawa 16
Changsha 15
Centro 13
Grafing 13
Madrid 13
Boydton 12
Florence 12
Leawood 12
San Giovanni la Punta 12
Amsterdam 11
Belo Horizonte 11
Brussels 11
Cagliari 11
Moscow 11
Tianjin 11
Bari 10
Pozzallo 10
Turku 10
Washington 10
Guangzhou 9
Lappeenranta 9
New York 9
Seattle 9
Augusta 8
Redmond 8
Santiago de Compostela 8
Bologna 7
Curitiba 7
East Stroudsburg 7
Gravina di Catania 7
Hanoi 7
Jinan 7
Ningbo 7
Norwalk 7
Phoenix 7
Rimini 7
Terrassa 7
Vienna 7
Den Haag 6
Kunming 6
Marseille 6
Mascalucia 6
Osio Sotto 6
Paris 6
Porto Sant'Elpidio 6
Poznan 6
Redwood City 6
Salvador 6
San Francisco 6
Scafati 6
Valencia 6
Aci Catena 5
Brooklyn 5
Totale 5.774
Salva come PNG Salva come JPEG
Nome #
C-5'-Triazolyl-2'-oxa-3'-aza-4'a-carbanucleosides: Synthesis and biological evaluation 420
Comprehensive data on a 2D-QSAR model for Heme Oxygenase isoform 1 inhibitors 218
Composti inorganici [Cap. 6] 201
Involvement of sigma 2 receptor on motor disorder 169
Antioxidant properties and pharmacokinetic studies of new selective σ1 bifunctional ligands 132
Design, synthesis, and pharmacological evaluation of NO donor-sigma receptors hybrids for the treatment of cancer 128
Design, synthesis, in vitro evaluation, and molecular modeling studies of N-substituted benzomorphans, analogs of LP2, as novel MOR ligands 127
Influenza del N-sostituente della (–)-cis-N-Normetazocina nella modulazione del profilo funzionale al MOR, DOR e KOR: da agonista ad antagonista attraverso ligandi misti agonisti/antagonisti 120
Exploiting the Power of Stereochemistry in Drug Action: 3-[(2S,6S,11S)-8-Hydroxy-6,11-dimethyl-1,4,5,6-tetrahydro-2,6-methano-3-benzazocin-3(2H)-yl]-N-phenylpropanamide as Potent Sigma-1 Receptor Antagonist 111
[1]Benzothieno[3,2-d]pyrimidine derivatives as ligands for the serotonergic 5-HT7 receptor 107
Combination of heme oxygenase-1 inhibition and sigma receptor modulation for anticancer activity 107
Development of a Sigma-2 Receptor affinity filter through a Monte Carlo based QSAR analysis 104
DNA intercalators based on (1,10-phenanthrolin-2-yl)isoxazolidin-5-yl core with better growth inhibition and selectivity than cisplatin upon head and neck squamous cells carcinoma 99
Synthesis and Structure-Activity Relationships of LP1 Derivatives: N-Methyl-N-phenylethylamino Analogues as Novel MOR Agonists 99
Novel N-Substituted Benzomorphan-Based Compounds: From MOR-Agonist/DOR-Antagonist to Biased/Unbiased MOR Agonists 99
4-Nitro-2,1,3-benzoxadiazole derivatives as potential fluorescent sigma receptor probes 94
(+)-and (−)-Phenazocine enantiomers: evaluation of their dual opioid agonist/σ1 antagonist properties and antinociceptive effects 93
Sigma-2 receptor ligands QSAR model dataset 92
Caspase-3 activation in human melanoma A375 cell line by a novel selective sigma-2 agonist 91
Haloperidol Metabolite II Valproate Ester (S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma 91
Antioxidant activity of (+)-Pentazocine on activated microglia 90
Development of Sigma Receptors Nitric Oxide Photodonor Ligands with Antiproliferative Activity 90
Antiangiogenic Effect of (±)-Haloperidol Metabolite II Valproate Ester [(±)-MRJF22] in Human Microvascular Retinal Endothelial Cells 90
Novel structural insight into inhibitors of heme oxygenase-1 (ho-1) by new imidazole-based compounds: Biochemical and in vitro anticancer activity evaluation 90
Synthesis of “no-light activated” Ciprofloxacin and Norfloxacin derivatives as potential biofilm dispersant agents 90
La modellistica molecolare applicata ai recettori Sigma-1 e Sigma-2: un excursus 88
Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines 87
A pseudouridine isoxazolidinyl nucleoside analogue structural analysis: A morphological approach 87
Heme Oxygenase Database (HemeOxDB) and QSAR Analysis of Isoform 1 Inhibitors 86
(+)-Methyl (1R,2S)-2-{[4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl]methyl}-1-phenylcyclopropanecarboxylate [(+)-MR200] Derivatives as Potent and Selective Sigma Receptor Ligands: Stereochemistry and Pharmacological Properties 86
Design of Small Molecules for Oncological and Neurodegenerative Diseases 85
Hyphenated 3D-QSAR statistical model-scaffold hopping analysis for the identification of potentially potent and selective sigma-2 receptor ligands 85
Fourfold filtered statistical/computational approach for the identification of imidazole compounds as HO-1 inhibitors from natural products 85
Tuning Properties for Blood-Brain Barrier Permeation: A Statistics-Based Analysis 84
S2RSLDB: A comprehensive manually curated, internet-accessible database of the sigma-2 receptor selective ligands 83
Dual Sigma-1 receptor antagonists and hydrogen sulfide-releasing compounds for pain treatment: Design, synthesis, and pharmacological evaluation 83
Molecular modeling studies of pseudouridine isoxazolidinyl nucleoside analogues as potential inhibitors of the pseudouridine 5'-monophosphate glycosidase 82
Adipocyte fatty acid binding protein 4 (FABP4) inhibitors. A comprehensive systematic review 81
A new Sigma-1 Receptor antagonist in Chronic Pain Treatment: (+)-2R/S-LP2 effects in inflammatory and neuropathic pain 79
Sigma-1 and Sigma-2 receptor ligands induce apoptosis and autophagy but have opposite effect on cell proliferation in uveal melanoma 79
A structure-and ligand-based virtual screening of a database of “small” marine natural products for the identification of “blue” sigma-2 receptor ligands 79
New selective Sigma-1/HDACi prodrugs for neurodegenerative disorders 77
Novel Sigma-1 receptor antagonists: From opioids to small molecules: What is new? 77
CNS permeability parameters determination through a statistical analysis driven approach 76
Synthesis of Novel Benzylpiperazine Derivatives as Ligands for the σ1 Receptor 75
Tumor Targeting Sigma Receptor Ligands: Development of New Molecular Hybrids as Anticancer Therapeutics 75
Antitrypanosomal lead discovery: Identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth 75
Nitric Oxide Photo-Donor Hybrids of Ciprofloxacin and Norfloxacin: A Shift in Activity from Antimicrobial to Anticancer Agents 74
Heme Oxygenase-2 (HO-2) as a therapeutic target: Activators and inhibitors 74
In vitro and in vivo pharmacological evaluation of LP1, a benzomorphan-based compound 72
Morphing of ibogaine: A successful attempt into the search for sigma-2 receptor ligands 71
Cytotoxicity Profiles and Neuroprotective Properties of the Novel Ifenprodil Analogues as Sigma Ligands 70
Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands 70
Heme Oxygenase-1: A new druggable target in the management of chronic and acute myeloid leukemia 69
Design, synthesis, and biological evaluation of new hybrid MOR agonist/HDACi compounds: an innovative approach for persistent pain management 68
Novel Sigma Receptors Ligands-Nitric Oxide Photodonor: Molecular Hybrids for Double-Targeted Antiproliferative Effect 68
Role of the Nrf2/HO-1 axis in bronchopulmonary dysplasia and hyperoxic lung injuries 68
Design, Synthesis, and Cytotoxic Assessment of New Haloperidol Analogues as Potential Anticancer Compounds Targeting Sigma Receptors 67
Development of novel H2S-donor sigma receptor hybrids for the management of pain. 67
Development of NO-releasing sigma receptor hybrids as anticancer agents 66
Identification of Potentially Potent Heme Oxygenase 1 Inhibitors through 3D-QSAR Coupled to Scaffold-Hopping Analysis 66
Sigma Receptor Ligands Carrying a Nitric Oxide Donor Nitrate Moiety: Synthesis, In Silico, and Biological Evaluation 65
Design and synthesis of new benzomorphan LP1 analogues, an opioid ligand with low development of tolerance 63
In-vitro evaluation of a new benzomorphan-based ligand 63
Synthesis and structure-activity relationships of (–)-cis-N-normetazocine-based LP1 derivatives 63
Potholing of the hydrophobic heme oxygenase-1 western region for the search of potent and selective imidazole-based inhibitors 63
Synthesis and in vitro opioid receptor studies on benzomorphan-based compounds: LP1, a potent and long-acting antinociceptive 62
Haloperidol Metabolite II Valproate Ester: Antiangiogenic Activity in Human Microvascular Retinal Endothelial Cells 61
Novel N-normetazocine Derivatives with Opioid Agonist/Sigma-1 Receptor Antagonist Profile as Potential Analgesics in Inflammatory Pain 60
Synthesis, in vitro and in silico studies of HO-1 inducers and lung antifibrotic agents 60
Discovery of first novel sigma/HDACi dual-ligands with a potent in vitro antiproliferative activity 59
Evaluation of pyrrolidine and pyrazolone derivatives as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1) 59
Potholing of the hydrophobic heme oxygenase-1 western region for the search of potent and selective imidazole-based inhibitors 58
Structure-activity relationships of mixed σ1R/σ2R ligands with antiproliferative and anticancer effects 57
Evaluation of N-substitution in 6,7-benzomorphan compounds 56
Recent advances in drug discovery of phototherapeutic non-porphyrinic anticancer agents 56
Pain management: new long-acting opioid ligands 56
Repurposing of human kinase inhibitors in neglected protozoan diseases 54
Series of Alkynyl-Substituted Thienopyrimidines as Inhibitors of Protozoan Parasite Proliferation 54
New Insights into the Opioid Analgesic Profile of cis-(-)-N-Normetazocine-derived Ligands 53
Synthesis and evaluation of haloperidol metabolite II prodrugs as anticancer agents 52
Development of new benzomorphan LP1 analogues 52
Interaction of new sigma ligands with biomembrane models evaluated by differential scanning calorimetry and Langmuir-Blodgett studies 52
Repurposing human PDE4 inhibitors for neglected tropical diseases: design, synthesis and evaluation of cilomilast analogues as Trypanosoma brucei PDEB1 inhibitors 51
Synthesis, Computational Insights, and Evaluation of Novel Sigma Receptors Ligands 50
Designing drugs optimized for both blood-brain barrier permeation and intra-cerebral partition 49
Exploring Structural Requirements for Sigma-1 Receptor Linear Ligands: Experimental and Computational Approaches 49
Discovery of 3-(2-aminoethyl)-thiazolidine-2,4-diones as a novel chemotype of sigma-1 receptor ligands 49
Identification and characterization of hundreds of potent and selective inhibitors of Trypanosoma brucei growth from a kinase-targeted library screening campaign 48
Heme Oxygenase-1 Inhibition: A Novel Strategy for the Design of Azole-Based Antitumour Agents 47
Targeting Heme Oxygenase-1 to Overcome Imatinib Resistance in Chronic Myeloid Leukemia 47
Identification of “Preferred” Human Kinase Inhibitors for Human African Trypanosomiasis Through a Statistical Analysis-Driven Approach 44
Novel selective ligands for the serotonergic 5-HT7 receptor: tricyclic derivatives Bearing the pyrimido-4(3H)-one ring 44
New homo and hetero bis-arylpiperazine and bis-benzylpiperazine derivatives as 5-HT7R selective ligands: design and synthesis 44
Identification of “Preferred” Human Kinase Inhibitors for Sleeping Sickness Lead Discovery. Are Some Kinases Better than Others for Inhibitor Repurposing? 44
Hybrid MOR agonist/HDACi molecules as potential antinociceptive multi-target drugs: design, synthesis, and biological evaluation 43
Synthesis and pharmacological evaluation of indole-based sigma receptor ligands 43
MOR/DOR Dual-Target Approach: 2S-LP2 Effects in Inflammatory and Neuropathic Pain 43
H2S releasing molecules in pharmaceutical development 42
Correction to Nitric Oxide Photo-Donor Hybrids of Ciprofloxacin and Norfloxacin: A Shift in Activity from Antimicrobial to Anticancer Agents 41
Totale 7.972
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.658
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.658
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021361 10 8 35 44 121 8 34 2 20 5 44 30
2021/2022718 61 100 31 17 115 5 105 31 42 20 10 181
2022/20231.918 138 124 30 241 116 248 10 501 348 34 91 37
2023/20241.101 56 150 57 60 75 310 66 44 6 21 177 79
2024/20253.577 120 493 145 264 586 424 333 179 322 240 227 244
2025/2026159 159 0 0 0 0 0 0 0 0 0 0 0
Totale 8.809